Metraipolis › archive › dc_cb124461dcab

A genomic-led strategy to anticipate drug safety effects — Europe PMC PPR:PPR1083598

Source
Europe PMC
Original
https://europepmc.org/article/PPR/PPR1083598
DOI
10.1101/2025.09.11.25335448
License (as archived)
CC0-1.0
Archived
2026-10-06T12:47:04.255Z
SHA-256 of the archived text
dedd7d869f08fa3c12fb326113a52251b4c61954bb215a763541f44d837e8c58
Stable URL of this page
https://metraipolis.com/documento/dc_cb124461dcab

How to cite

A genomic-led strategy to anticipate drug safety effects — Europe PMC PPR:PPR1083598 — Europe PMC, https://europepmc.org/article/PPR/PPR1083598 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_cb124461dcab (Metraipolis archive dc_cb124461dcab, sha256 dedd7d869f08fa3c12fb326113a52251b4c61954bb215a763541f44d837e8c58)
BibTeX
@misc{dccb124461dcab,
  title = {A genomic-led strategy to anticipate drug safety effects — Europe PMC PPR:PPR1083598},
  howpublished = {Europe PMC},
  url = {https://europepmc.org/article/PPR/PPR1083598},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_cb124461dcab; sha256 dedd7d869f08fa3c12fb326113a52251b4c61954bb215a763541f44d837e8c58},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC, https://europepmc.org/article/PPR/PPR1083598. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Safety-related issues account for approximately 28% of failures in new drug discovery programs. On top of that, many are discovered during post-marketing surveillance, significantly limiting drug utility and application. To proactively address these concerns, we developed a genetics-led strategy leveraging Mendelian Randomization (MR) across large-scale genetic datasets from the Million Veteran Program, FinnGen, and UK Biobank. By mapping genetic variants associated with gene expression and protein abundance to 1,449 harmonized human phenotypes, we systematically identified potential adverse drug reactions (ADR). Our extensive MR analysis, encompassing 16,915 protein-coding genes, demonstrated the capacity to predict hundreds of known ADR for approved medications, with approximately 40% corroborated by FDA Adverse Event Reporting System (FAERS) data. Additionally, we found significant enrichment of identified gene-mechanism pairs in clinical trials terminated early due to safety concerns, highlighting the clinical utility of genetics-informed safety prediction. Notably, immune-related pathways were prominently associated with ADR, indicating particular sensitivity within immune modulation targets. Our comprehensive atlas, integrating genetic evidence with pharmacological mechanisms, provides a robust predictive framework for anticipating drug safety, potentially enhancing decision-making in drug development and pharmacovigilance.

Tema degli esploratori: scienze della vita e salute (ricerca Europe PMC «genetics», solo open access).
Pubblicazione: medRxiv, 2025 (prima pubblicazione 2025-09-14).
Identificativi: DOI 10.1101/2025.09.11.25335448.
Pagina: https://europepmc.org/article/PPR/PPR1083598 — https://doi.org/10.1101/2025.09.11.25335448. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T11:02:32.820Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.